HBM Holdings (HKG:2142) expects a profit of between 7.3 million yuan and 22 million yuan for 2024, compared with $22.8 million in 2023, a Friday bourse filing said.
The biotech company attributed the forecast to growth in its recurring revenue, cost control, and partnerships with pharmaceutical and biotech companies worldwide.